StockData
Neuphoria Therapeutics Inc. logo

Neuphoria Therapeutics Inc. (NEUP) stock

NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 18, 2026Score 5/30
$2.27−0.21 (-8.47%)

Close on Nov 17, 2026Market cap $68.24KP/E –Yield –

Neuphoria Therapeutics net income

Net income is the profit left for shareholders after every expense, interest and tax.

Neuphoria Therapeutics's net income for the twelve months ending Jun 30, 2026 was -$13.45M. For fiscal 2026 it was -$13.45M.

Annual net income

PeriodPeriod endValueChange
FY2026Jun 30, 2026-$13.45M–
FY2025Jun 30, 2025-$369.63K–
FY2024Jun 30, 2024-$15.49M–
FY2023Jun 30, 2023-$21.38M–

Quarterly net income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jun 30, 2026-$4.90M–
Q3 FY2026CQ1 2026Mar 31, 2026-$505.06K-104.5%
Q2 FY2026CQ4 2025Dec 31, 2025$1.86M–
Q1 FY2026CQ3 2025Sep 30, 2025-$9.91M–
Q4 FY2025CQ2 2025Jun 30, 2025-$8.88M–
Q3 FY2025CQ1 2025Mar 31, 2025$11.26M–
Q2 FY2025CQ4 2024Dec 31, 2024-$1.94M–
Q1 FY2025CQ3 2024Sep 30, 2024-$804.79K–
Q4 FY2024CQ2 2024Jun 30, 2024-$2.69M–
Q3 FY2024CQ1 2024Mar 31, 2024-$2.78M–
Q2 FY2024CQ4 2023Dec 31, 2023-$4.55M–
Q1 FY2024CQ3 2023Sep 30, 2023-$5.47M–

More Neuphoria Therapeutics figures

See a number that looks wrong?